Scarica l'app Stockscreener
0.00
100.00%
-2.11
Dopo l'orario di chiusura:
2.15
2.15
+
Precedente Chiudi:
$2.11
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$45.72M
Reddito:
-
Utile/perdita netta:
$-12.94M
Rapporto P/E:
0.00
EPS:
-2.84
Flusso di cassa netto:
$-13.83M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$7.42
Aileron Therapeutics Inc Stock (ALRN) Company Profile
Nome
Aileron Therapeutics Inc
Settore
Industria
Telefono
(737) 802-1989
Indirizzo
12407 N. MOPAC EXPY., AUSTIN, MA
Confronta ALRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALRN
Aileron Therapeutics Inc
|
0.00 | 45.72M | 0 | -12.94M | -13.83M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2017-07-24 | Iniziato | BofA/Merrill | Buy |
| 2017-07-24 | Iniziato | Jefferies | Buy |
| 2017-07-24 | Iniziato | William Blair | Outperform |
Aileron Therapeutics Inc Borsa (ALRN) Ultime notizie
Theratechnologies (NASDAQ:THTX) vs. Aileron Therapeutics (NASDAQ:ALRN) Head to Head Survey - Defense World
Aileron Therapeutics Reports Q3 2024 Financial Results - MSN
Aileron Therapeutics, Inc. announced that it has received $42 million in funding from a group of investors. - Marketscreener.com
Aileron straps in for 2025 with a new name: Rein Therapeutics - FiercePharma
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - Marketscreener.com
Aileron Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Aileron Therapeutics, Inc. Announces Board Changes -April 01, 2019 at 06:16 am EDT - Marketscreener.com
Aileron Therapeutics to be Included in the Russell Microcap® Index - Marketscreener.com
Aileron Therapeutics Announces Appointments to Scientific Advisory Board -March 28, 2018 at 07:00 am EDT - Marketscreener.com
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer - Marketscreener.com
Aileron Therapeutics Announces Board Appointments - Marketscreener.com
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Marketscreener.com
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - Marketscreener.com
Aileron Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Aileron Therapeutics Announces Management Changes - Marketscreener.com
Aileron Therapeutics, Inc. Announces CEO Changes - Marketscreener.com
Aileron Therapeutics Announces Management Changes -September 06, 2018 at 09:10 am EDT - Marketscreener.com
Rein Therapeutics announces name change and new ticker By Investing.com - Investing.com Canada
Rein Therapeutics announces name change and new ticker - Investing.com
Aileron Therapeutics announces rebranding to Rein Therapeutics - MSN
Geode Capital Management LLC Grows Position in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - Defense World
Geode Capital Management LLC Boosts Stock Position in Pro-Dex, Inc. (NASDAQ:PDEX) - Defense World
Aileron Therapeutics Announces Rebranding to Rein Therapeutics - PR Newswire
RNTXRein Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aileron Therapeutics to Present at the 8th Annual IPF Summit - The Eastern Progress Online
Aileron Therapeutics CEO James Brian Windsor buys $897 in stock By Investing.com - Investing.com Nigeria
Aileron Therapeutics CEO James Brian Windsor buys $897 in stock - Investing.com
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - The Eastern Progress Online
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest - MarketBeat
Chemotherapy Induced Anemia Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - Barchart
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Citizentribune
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in October - MarketBeat
Aileron Therapeutics Inc (ALRN) Quarterly 10-Q Report - Quartzy
Aileron Reports Positive Phase 1b Data for IPF Drug, Shows Strong Biomarker Response | ALRN Stock News - StockTitan
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis - AOL
Aileron reports promising phase 1b trial results for IPF treatment - Investing.com
Aileron reports promising phase 1b trial results for IPF treatment By Investing.com - Investing.com UK
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Nasdaq
Advancium explores ALRN-6924 for pediatric eye cancer treatment - Investing.com India
Advancium explores ALRN-6924 for pediatric eye cancer treatment By Investing.com - Investing.com Canada
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Drops By 14.2% - MarketBeat
Constrained Peptide Drugs Market Size, Scope and Share Analysis - InsightAce Analytic
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Increases By 15.8% - MarketBeat
ALRNAileron Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis - Lelezard
University of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Nantahala Capital Management LLC Raises Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in September - MarketBeat
Aileron Therapeutics Inc Azioni (ALRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.82%
0.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):